News
31 March 2020

EIB finances AM-Pharma's development of acute kidney injury treatment

In:
Infrastructure
Region:
Europe

The EIB and Utrecht-based AM-Pharma have signed a €24 million financing agreement. The funds will be used to accelerate the development of the clinical stage biopharmaceutical company’s recombinant alkaline phosphatase enzyme, which is used to treat acute kidney injury (AKI). The...

Exclusive subscriber content…

If you are a TXF subscriber, please login to continue reading

Login

Not yet a subscriber? Join us today to continue accessing content without any restrictions

View our subscription options

Or to request access to TXF Intelligence contact us

Request Access

You might also like


Perspective
23 June 2026

TXF Global 2026: A wider ECA umbrella

The next phase of export, agency, and project finance will be defined by strategic collaboration, regulatory modernisation, and a broader ECA mandate. Here are the main...

Perspective
29 June 2026

Wishes from Prague: When TXF gave a magic wand to ECAs and...

Prague Exile Global 2026 was magical. TXF asked 13 of the ECA and DFI leaders on the hotseat a variant on the question: “If you had a magic wand, what one change would you...